

Ruchan Uslu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6981477/publications.pdf>

Version: 2024-02-01

129
papers

2,100
citations

270111

25
h-index

312153

41
g-index

131
all docs

131
docs citations

131
times ranked

3827
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. <i>Cancer Investigation</i> , 2022, 40, 199-209.	0.6	1
2	Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1369-1378.	0.5	31
3	Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. <i>Annals of Oncology</i> , 2021, 32, 1245-1255.	0.6	35
4	Contribution of "complete response to treatment" to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis. <i>PLoS ONE</i> , 2021, 16, e0259622.	1.1	0
5	The Relationship Between Nutritional Status, Performance Status, and Survival Among Pancreatic Cancer Patients. <i>Nutrition and Cancer</i> , 2020, 72, 202-208.	0.9	19
6	Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 583-588.	0.4	20
7	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	0.6	78
8	Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma. <i>Indian Journal of Cancer</i> , 2019, 56, 4.	0.2	3
9	Are BRAF V600E and K-Ras Mutations Associated With Tumor Aggressiveness in Well-Differentiated Thyroid Cancer?. <i>International Surgery</i> , 2019, 104, 99-106.	0.0	0
10	Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors. <i>Jbuon</i> , 2019, 24, 779-790.	0.3	5
11	Is neuropathic pain associated with cardiac sympathovagal activity changes in patients with breast cancer?. <i>Neurological Research</i> , 2018, 40, 297-302.	0.6	4
12	The effect of chemotherapy on nutritional status and weakness in geriatric gastrointestinal system cancer patients. <i>Nutrition</i> , 2018, 47, 39-42.	1.1	17
13	AT-101 acts as anti-proliferative and hormone suppressive agent in mouse pituitary corticotroph tumor cells. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 233-240.	1.8	6
14	OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, S331-S332.	0.5	2
15	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1468-1479.	5.1	370
16	Angiogenesis inhibition on glioblastoma multiforme cell lines (U-87MG and T98G) by AT-101. <i>Journal of Oncological Science</i> , 2018, 4, 65-69.	0.1	4
17	Can yoga have any effect on shoulder and arm pain and quality of life in patients with breast cancer? A randomized, controlled, single-blind trial. <i>Complementary Therapies in Clinical Practice</i> , 2018, 32, 40-45.	0.7	38
18	A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1223-1228.	1.0	3

#	ARTICLE	IF	CITATIONS
19	The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome. The Journal of Breast Health, 2018, 14, 211-217.	0.4	13
20	Risk factors for poor mobilization in solid tumors: How effectively can we mobilize patients with solid tumors?. Transfusion and Apheresis Science, 2017, 56, 809-813.	0.5	1
21	The Effects of Compliance with Nutritional Counselling on Body Composition Parameters in Head and Neck Cancer Patients under Radiotherapy. Journal of Nutrition and Metabolism, 2017, 2017, 1-7.	0.7	35
22	Retrospective analysis of patients with relapsed or refractory testicular nonseminous germ cell tumors treated with autologous stem cell transplantation. Indian Journal of Cancer, 2017, 54, 415.	0.2	3
23	Characteristics of Turkish colorectal cancer patients and bevacizumab preference.. Journal of Clinical Oncology, 2017, 35, e15055-e15055.	0.8	0
24	Outcomes of Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2017, 35, e12517-e12517.	0.8	1
25	Follow-up of the Chronic HBV Infected Patients Planned Chemotherapy Due to Solid Organ Malignancy. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2017, 27, 213-219.	0.1	0
26	Reliability and validity of the Turkish version of the EORTC QLQ-C15-PAL for patients with advanced cancer. Palliative and Supportive Care, 2016, 14, 628-634.	0.6	13
27	Pazopanib: a novel treatment option for aggressive fibromatosis. Clinical Sarcoma Research, 2016, 6, 22.	2.3	6
28	Comparative analysis of XTT assay and xCELLigence system by measuring cytotoxicity of resveratrol in human cancer cell lines. Turkish Journal of Biochemistry, 2016, 41, 413-421.	0.3	4
29	Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. Journal of Oncology Pharmacy Practice, 2016, 22, 46-53.	0.5	18
30	Ocreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells. Tumor Biology, 2016, 37, 4939-4944.	0.8	7
31	Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway. Tumor Biology, 2016, 37, 3665-3673.	0.8	4
32	Abstract P4-13-09: Clinical effectiveness of everolimus and exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study. , 2016, , .		2
33	A Retrospective Comparative Study Of Intrinsic Molecular Breast Cancer Subtypes Between Young And Elderly Women With Breast Cancer.. Journal of Clinical Oncology, 2016, 34, e12063-e12063.	0.8	0
34	Determining the satisfaction levels of the family members of patients with advanced-stage cancer. Palliative and Supportive Care, 2015, 13, 741-747.	0.6	4
35	Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncology Letters, 2015, 10, 2598-2602.	0.8	11
36	Importance of surveillance and risk factor evaluation in patients with multiple curable malignancies. European Journal of Cancer Prevention, 2015, 24, 363.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells. PLoS ONE, 2015, 10, e0141090.	1.1	27
38	Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315. Journal of Oncology Pharmacy Practice, 2015, 21, 318-319.	0.5	2
39	The Role of Body Mass Index in Triple Negative Breast Cancer. Oncology Research and Treatment, 2015, 38, 518-522.	0.8	13
40	Evaluating Palliative Care Needs in Middle Eastern Countries. Journal of Palliative Medicine, 2015, 18, 18-25.	0.6	59
41	Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations. International Journal of Clinical Oncology, 2015, 20, 395-404.	1.0	8
42	Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines. Cancer Chemotherapy and Pharmacology, 2015, 75, 1273-1280.	1.1	11
43	Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast Cancer, 2015, 22, 480-485.	1.3	3
44	Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines. Tumor Biology, 2015, 36, 779-786.	0.8	3
45	Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K/AKT pathway. Clinical and Translational Oncology, 2015, 17, 145-151.	1.2	62
46	Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12656-e12656.	0.8	0
47	Turkish National Gastric Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12645-e12645.	0.8	0
48	Cytotoxic effects of cabazitaxel on human gliomaspheres and monolayer glioma cells: A comparative study between 2D and 3D cell cultures.. Journal of Clinical Oncology, 2015, 33, e13049-e13049.	0.8	0
49	Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12653-e12653.	0.8	0
50	Prognostic effect of tumor location in stage II and III colon cancer.. Journal of Clinical Oncology, 2015, 33, e14652-e14652.	0.8	0
51	Prognostic role of neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with docetaxel.. Journal of Clinical Oncology, 2015, 33, e16050-e16050.	0.8	0
52	Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.. Journal of Clinical Oncology, 2015, 33, e11579-e11579.	0.8	2
53	Expression profiling of stem cell signaling alters with spheroid formation in CD133high/CD44high prostate cancer stem cells. Oncology Letters, 2014, 7, 2103-2109.	0.8	42
54	Comparison of Molecular Subtypes of Breast Cancer in Women ≤35 Years and > 35 Years: Does Age Matter?. Annals of Oncology, 2014, 25, iv126.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 166-170.	0.4	3
56	Cancer stem cell differentiation: TGF β 21 and versican may trigger molecules for the organization of tumor spheroids. <i>Oncology Reports</i> , 2014, 32, 641-649.	1.2	45
57	Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer. <i>Tumori</i> , 2014, 100, 370-6.	0.6	5
58	Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 7119-7123.	0.5	15
59	Anticancer Therapy for Breast Cancer Patients with Skin Metastases Refractory to Conventional Treatments. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 1885-1887.	0.5	6
60	First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 3157-3161.	0.5	2
61	Effect of trastuzumab/AT-101 combination on apoptosis and cytotoxicity in HER2-positive breast cancer cells: A novel combination to effect resistance to anti-HER2 therapy through inhibition of PI3K signaling.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13512-e13512.	0.8	0
62	Use of docetaxel in combination with octreotide as a synergistic combination for prostate cancer with apoptotic and antiangiogenic effects.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13515-e13515.	0.8	0
63	Enhancement of docetaxel efficacy by zoledronic acid pretreatment in docetaxel-resistant prostate cancer cells (PC-3/R and DU-145/R).. <i>Journal of Clinical Oncology</i> , 2014, 32, e16105-e16105.	0.8	0
64	Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. <i>Molecular Biology Reports</i> , 2013, 40, 3925-3933.	1.0	37
65	Effects of exercise on angiogenesis and apoptosis-related molecules, quality of life, fatigue and depression in breast cancer patients. <i>European Journal of Cancer Care</i> , 2013, 22, 626-637.	0.7	84
66	A diverse induction of apoptosis by trabectedin in MCF-7 (HER2 β /ER+) and MDA-MB-453 (HER2+/ER β) breast cancer cells. <i>Toxicology Letters</i> , 2013, 221, 128-136.	0.4	38
67	Secondary haematological malignancies in the BCIRG 001 study. <i>Lancet Oncology</i> , The, 2013, 14, e87-e88.	5.1	2
68	Predictive and prognostic values of Tau and BubR1 protein in prostate cancer and their relationship to the Gleason score. <i>Medical Oncology</i> , 2013, 30, 526.	1.2	15
69	HER2-Pozitif Meme Kanseri HastalarÄ±nda Rac1 Ekspresyonunun Trastuzumab Direnci Ä°le Ä°liÅkisi. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2013, 23, 219-226.	0.1	1
70	Examination of Pain Experiences of Cancer Patients in Western Turkey. <i>Holistic Nursing Practice</i> , 2013, 27, 358-365.	0.3	6
71	Comparing Time to Disease Progression of Irinotecan and Oxaliplatin-based Chemotherapies in Colorectal Cancer Patients With Liver Only Metastasis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 388-391.	0.6	5
72	Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III 'Stop and Go' Study Results - A Turkish Oncology Group Trial. <i>Oncology</i> , 2013, 85, 328-335.	0.9	59

#	ARTICLE	IF	CITATIONS
73	P53 Modulates Trabectedin Mediated Cytotoxicity in Glioblastoma Multiforme Cells (U-87MG and Tj ETQq1 1 0.784314 rgB ₀ /Overlook	0.6	0
74	Radiosensitization of HER2-positive breast cancer cell lines with trastuzumab.. Journal of Clinical Oncology, 2013, 31, e11501-e11501.	0.8	2
75	Paclitaxel in combination with AT-101 induces apoptosis via supressing Bcl-2, bcl-XL, mcl-1 proteins in human breast cancer cells.. Journal of Clinical Oncology, 2013, 31, e13578-e13578.	0.8	1
76	Abstract 255: Expressionprofiling of stem cell signaling alters with spheroid formation in CD133high/CD44highprostate cancer stem cells.. , 2013, , .		0
77	Abstract 4072: Wnt1 gene expression alters heterogeneous population of prostate cancer cells; decreased expression pattern observed in CD133+/CD44+prostate cancer stem cells.. , 2013, , .		0
78	Understanding international genomic diversity for breast cancer: Comparison of molecular subtypes of breast cancer in very young women (age â‰‰ 35) between Izmir (Western Turkey) and Boston (Massachusetts, USA).. Journal of Clinical Oncology, 2013, 31, e12509-e12509.	0.8	0
79	Capecitabine maintenance therapy after docetaxel/capecitabine combination chemotherapy in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2013, 31, e12018-e12018.	0.8	0
80	Trabectedin to induce mitochondrial membrane potential dissipation and reactive oxygen species generation in breast cancer cells.. Journal of Clinical Oncology, 2013, 31, e13580-e13580.	0.8	0
81	The Frequency and Significance of Radiologically Detected Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer. Medical Principles and Practice, 2012, 21, 457-461.	1.1	13
82	Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormoneâ€refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. BJU International, 2012, 110, E1147-54.	1.3	14
83	Effects ofThymus serpyllumExtract on Cell Proliferation, Apoptosis and Epigenetic Events in Human Breast Cancer Cells. Nutrition and Cancer, 2012, 64, 1245-1250.	0.9	37
84	Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1155-1163.	1.2	21
85	Undifferentiated embryonal sarcoma of the liver in an adult patient: Case report. Turkish Journal of Gastroenterology, 2012, 23, 279-283.	0.4	8
86	Abstract OT1-1-08: Clinical outcomes among ErbB2+ MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).. , 2012, , .		0
87	Cancer patientsâ€™ satisfaction with doctors and preferences about death in a university hospital in Turkey. Patient Education and Counseling, 2011, 85, e285-e290.	1.0	9
88	Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines. Molecular Biology Reports, 2011, 38, 249-259.	1.0	17
89	p53 Protein Accumulation and Presence of Visceral Metastasis Are Independent Prognostic Factors for Survival in Patients with Metastatic Inflammatory Breast Carcinoma. Medical Principles and Practice, 2011, 20, 159-164.	1.1	7
90	Targeting Bcl-2 Protein to Enhance Chemosensitivity of Hormone Refractory Prostate Cancer Cell Line, DU-145 by a Synergistic Combination of Docetaxel and Gossypol. Turkiye Klinikleri Journal of Medical Sciences, 2011, 31, 859-866.	0.1	1

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. <i>Medical Oncology</i> , 2010, 27, 585-591.	1.2	12
92	Evaluation of burnout syndrome in oncology employees. <i>Medical Oncology</i> , 2010, 27, 968-974.	1.2	58
93	Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination. <i>Molecular Biology Reports</i> , 2010, 37, 1269-1277.	1.0	29
94	Assessment of pain, fatigue, sleep and quality of life (QoL) in elderly hospitalized cancer patients. <i>Archives of Gerontology and Geriatrics</i> , 2010, 51, e57-e61.	1.4	34
95	Apoptosis-Mediated Cytotoxic Effects of Ibandronic Acid on Hormone- and Drug-Refractory Prostate Cancer Cells and Human Breast Cancer Cells. <i>Journal of International Medical Research</i> , 2010, 38, 1663-1672.	0.4	2
96	Comparison of XTT and Alamar blue assays in the assessment of the viability of various human cancer cell lines by AT-101 (gossypol). <i>Toxicology Mechanisms and Methods</i> , 2010, 20, 482-486.	1.3	31
97	Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 102.	3.5	17
98	Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU145, by gossypol/zoledronic acid combination. <i>Cell Biology International</i> , 2009, 33, 1165-1172.	1.4	8
99	The frequency of fibromyalgia syndrome and quality of life in hospitalized cancer patients. <i>European Journal of Cancer Care</i> , 2009, 18, 195-201.	0.7	11
100	Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. <i>BJU International</i> , 2009, 104, 107-114.	1.3	19
101	Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. <i>Cell Biology International</i> , 2009, 33, 239-246.	1.4	38
102	Hopelessness in Turkish cancer inpatients: The relation of hopelessness with psychological and disease-related outcomes. <i>European Journal of Oncology Nursing</i> , 2009, 13, 81-86.	0.9	27
103	Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs. <i>Medical Hypotheses</i> , 2009, 73, 606-607.	0.8	2
104	Can gossypol be a hope for transsexual patients (male to female) before sex reassignment surgery? Just for adjusting the body to mind. <i>Medical Hypotheses</i> , 2009, 73, 625-626.	0.8	2
105	Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. <i>European Cytokine Network</i> , 2009, 20, 121-130.	1.1	19
106	Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 37.	3.5	23
107	Comparison of Inflammatory Breast Cancer and Noninflammatory Breast Cancer in Western Turkey. <i>Medical Principles and Practice</i> , 2008, 17, 475-480.	1.1	4
108	Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. <i>European Cytokine Network</i> , 2008, 19, 176-84.	1.1	14

#	ARTICLE	IF	CITATIONS
109	Serum Her-2/neu and Survivin Levels and Their Relationship to Histological Parameters in Early-stage Breast Cancer. <i>Journal of International Medical Research</i> , 2007, 35, 165-172.	0.4	19
110	Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 532-537.	1.2	7
111	Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1552-1556.	1.2	10
112	Single-Agent Irinotecan for Recurrent/Metastatic Colorectal Cancer: A Retrospective Analysis. <i>Medical Principles and Practice</i> , 2006, 15, 288-292.	1.1	3
113	Potential Predictive Factors for Response to Weekly Paclitaxel Treatment in Patients with Metastatic Breast Cancer. <i>Journal of Chemotherapy</i> , 2005, 17, 96-103.	0.7	15
114	Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 240-245.	1.2	27
115	Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 1486-1492.	0.6	28
116	Topotecan in Platinum-Resistant Epithelial Ovarian Cancer. <i>Chemotherapy</i> , 2005, 51, 347-351.	0.8	8
117	Differential Effects of Doxorubicin and Docetaxel on Nitric Oxide Production and Inducible Nitric Oxide Synthase Expression in MCF-7 Human Breast Cancer Cells. <i>Oncology Research</i> , 2004, 14, 381-386.	0.6	14
118	Which dosing scheme is suitable for the taxanes? an in vitro model. <i>Archives of Pharmacal Research</i> , 2002, 25, 550-555.	2.7	6
119	The Urinary Excretion of Glycosaminoglycans and Heparan Sulphate in Lupus Nephritis. <i>Clinical Rheumatology</i> , 2002, 21, 284-288.	1.0	6
120	Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. <i>Leukemia Research</i> , 2002, 26, 391-398.	0.4	24
121	Doxazosin: a new cytotoxic agent for prostate cancer?. <i>BJU International</i> , 2001, 85, 672-675.	1.3	21
122	Up-regulation of serine/threonine protein phosphatase type 2A regulatory subunits during methylprednisolone-induced differentiation of leukaemic HL-60 cells. <i>International Journal of Laboratory Hematology</i> , 2000, 22, 271-274.	0.2	8
123	Augmentation of methylprednisolone-induced differentiation of myeloid leukemia cells by serine/threonine protein phosphatase inhibitors. <i>Leukemia Research</i> , 1999, 23, 507-512.	0.4	22
124	Superior vena cava syndrome together with multiple venous thrombosis in Behçet's disease. <i>Clinical Rheumatology</i> , 1998, 17, 176-177.	1.0	16
125	Sensitization of Human Ovarian Tumor Cells by Subtoxic CDDP to Anti-Fas Antibody-Mediated Cytotoxicity and Apoptosis. <i>Gynecologic Oncology</i> , 1996, 62, 282-291.	0.6	39
126	Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor- α and cis-diamminedichloroplatinum. <i>Cancer</i> , 1996, 77, 725-732.	2.0	33

#	ARTICLE	IF	CITATIONS
127	Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. <i>Oncology Reports</i> , 0, , .	1.2	1
128	Determine symptoms experienced by the patients with advanced cancer and the factors affecting them. <i>Turk Onkoloji Dergisi</i> , 0, , .	0.0	0
129	Central Line-associated <i>Pantoea</i> spp. Bacteremia and Solid Organ Malignancy: A Report of Two Cases. <i>Mediterranean Journal of Infection, Microbes and Antimicrobials</i> , 0, 7, .	0.2	0